Tech Company Financing Transactions
Avilar Therapeutics Funding Round
On 11/22/2021, Avilar Therapeutics raised $60 million in Seed funding from RA Capital.
Transaction Overview
Company Name
Announced On
11/22/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Seed
Investors
RA Capital (Josh Resnick)
Proceeds Purpose
Proceeds from financing have been allocated to developing Avilar's ATAC degrader platform and to systematically applying this platform to create a pipeline of ATAC therapeutics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St. 18th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Avilar is pioneering the next frontier in protein degradation by targeting extracellular proteins. Targeted protein degradation has emerged as a powerful new drug modality with applications in a broad range of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Grau
Chief Scientific Officer
Effie Tozzo
Vice President
Kevin Lumb
Vice President
Jason Wiles
VP - Bus. Development
Phil Graham
Browse more venture capital transactions:
Prev: 11/22/2021: Comet venture capital transaction
Next: 11/22/2021: Aimi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs